MediciNova, Inc. develops small-molecule therapeutics for inflammatory, fibrotic, and neurodegenerative diseases. The company's recurring updates center on MN-166, or ibudilast, and MN-001, or tipelukast, including programs involving amyotrophic lateral sclerosis, degenerative cervical myelopathy, progressive multiple sclerosis, chemotherapy-induced peripheral neuropathy, Long COVID, substance dependence, non-alcoholic fatty liver disease, hypertriglyceridemia, and idiopathic pulmonary fibrosis.
MediciNova news also covers clinical-trial progress, expanded-access activity, investigator-sponsored research, peer-reviewed translational studies, scientific and regulatory advisory matters, and corporate updates connected to its Nasdaq-listed common stock and Tokyo Stock Exchange listing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MediciNova, Inc. has announced a modification to its contract with BARDA to repurpose MN-166 (ibudilast) as a potential medical countermeasure against chlorine gas-induced lung damage. The contract extension lasts until May 31, 2023. MN-166, a small molecule compound, is in late-stage clinical development for various neurodegenerative diseases and is being evaluated for ARDS. MediciNova is focused on developing novel therapies for inflammatory and neurodegenerative diseases, with MN-166 currently in Phase 3 trials for ALS and DCM.
MediciNova, Inc. announced research findings from the glioblastoma clinical trial MN-166-GBM-1201, presented by Dr. Justin Lathia at the 20th Annual World Congress of SBMT. The study analyzed tumor tissues to identify predictors of treatment response to MN-166 and temozolomide. Results showed that responders had lower CD3+ T cell percentages and trends in CD74 expression compared to non-responders. Dr. Lathia highlighted MN-166's potential in enhancing CD3+ infiltration in glioblastoma patients. Chief Medical Officer Kazuko Matsuda noted the significance of these findings in addressing the challenges of glioblastoma treatment.
MediciNova has received authorization from Health Canada to initiate a multi-center, randomized clinical trial for MN-166 (ibudilast) targeting Long COVID treatment, under the RECLAIM trial. This Phase 2/3 trial aims to evaluate various therapies, including MN-166, with about 800-1000 patients expected to participate across Canada. The study will monitor improvements in patients' physical health over a 6-month period. This development highlights a significant unmet medical need for effective Long COVID interventions, potentially enhancing MediciNova's pipeline focused on inflammatory and neurodegenerative diseases.
MediciNova, Inc. has completed enrollment in a Phase 2b clinical trial of MN-166 (ibudilast) aimed at treating alcohol use disorder (AUD). This trial, funded by the National Institute on Alcohol Abuse and Alcoholism, includes 102 participants who will take MN-166 or a placebo over 12 weeks. The primary goal is to evaluate the reduction in heavy drinking days. Results from recent studies suggest MN-166 is a safe, promising treatment for AUD. The company is anticipating topline results following participant follow-up.
MediciNova announced the completion of enrollment in its Phase 2 clinical trial of MN-166 (ibudilast) for glioblastoma at Dana-Farber Cancer Institute. This trial includes a dose-escalation phase to determine safety and a fixed-dose phase to evaluate efficacy combined with temozolomide (TMZ). Preliminary results will be revealed at the 20th Annual World Congress of SBMT from February 16-19, 2023. Chief Medical Officer, Kazuko Matsuda, expressed optimism about potential predictors of treatment response and indicated further findings will be shared post-conference.